Oliver Sartor MDLaborde Professor, Cancer Research, Medicine and Urology Departments, Tulane School of Medicine, New Orleans, Louisiana
Dr. Oliver Sartor specializes in the treatment of prostate cancer patients in Louisiana. Dr. Sartor is the Laborde Professor of Cancer Research in the Medicine and Urology Departments of the Tulane School of Medicine. Prior to joining the Tulane faculty, Sartor served as an associate professor in the Lank Genitourinary Oncology Center at Harvard’s Dana-Farber Cancer Institute. He also serves as the chair-elect of the Department of Defense Prostate Cancer Integration Panel, which directs over $70 million in federal funding for prostate cancer research.
Previously, Dr. Sartor was the director of the Stanley S. Scott Cancer Center at Louisiana State University. He was also co-director of the Louisiana Cancer Research Consortium, a state established public-private partnership focused on oncology research in Louisiana.
Dr. Sartor was also an associate professor of medicine at Harvard Medical School.
Sartor is the editor-in-chief of the peer-reviewed, bimonthly journal Clinical Genitourinary Cancer. The journal is dedicated to disseminating cutting edge research to the practicing oncologist. He is the author of more than 100 scientific papers. He received his medical degree from Tulane University, and completed a fellowship with the National Cancer Institute. He is a member of several professional societies, including the American Society of Clinical Oncology, the American Association for Cancer Research, the American Urological Association, and the Society of Urologic Oncology, and board certified in internal medicine and medical oncology.
Oliver Sartor, MD serves as a consultant for Bayer Pharmaceutical, Bristol-Myers Squibb, Celgene Pharmaceutical, Dendreon, Johnson & Johnson, Medivation, Oncogenex Pharmaceutical, Sanofi-Aventis, and Tokai Pharmaceutical.
Oliver Sartor, MD has received research/grant support from Bayer Pharmaceutical, Endocyte Pharmaceutical, Innocrin Pharmaceutical, Johnson & Johnson, and Sanofi-Aventis.
Recent Contributions to PracticeUpdate:
- [177Lu]Lu-PSMA-617 vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
- ASCO GU 2021: Recommendations From Dr. Oliver Sartor
- Immunotherapy in the Treatment of Prostate Cancer
- Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer
- Prostate Radiotherapy With Adjuvant ADT Improves Metastasis-Free Survival Over Neoadjuvant ADT
- Androgen Deprivation Therapy and Radiotherapy in Intermediate-Risk Prostate Cancer
- Quality of Life in Patients With Metastatic Prostate Cancer Following Treatment With Cabazitaxel vs Abiraterone or Enzalutamide
- Apalutamide and Overall Survival in Prostate Cancer
- Treatment of Nonmetastatic Castration-Resistant Prostate Cancer With Darolutamide
- Germline Sequencing DNA Repair Genes in Aggressive vs Nonaggressive Prostate Cancer